Related Experiment Video

Updated: Jul 17, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Genetic polymorphisms and treatment response in advanced non-small cell lung cancer

Dan Su1, Shenglin Ma, Peng Liu

  • 1Department of Epidemiology and Public Health, Yale Cancer Center, Yale University School of Medicine, 60 College Street, New Haven, CT 06520-8034, USA.

Lung Cancer (Amsterdam, Netherlands)
|January 16, 2007
PubMed
Abstract

Insights

Genetic variations in ERCC1 and iASPP influence non-small cell lung cancer (NSCLC) treatment response. Specific single nucleotide polymorphisms (SNPs) in ERCC1 and iASPP are linked to chemotherapy and radiotherapy outcomes in NSCLC patients.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Genetic polymorphisms in DNA repair and apoptosis pathways are implicated in cancer treatment response.
  • Investigating these variations may predict patient outcomes in non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To evaluate the association between specific genetic variations and treatment response in advanced NSCLC patients.
  • To examine the impact of single nucleotide polymorphisms (SNPs) in ATM, ERCC1, APE1, and iASPP on chemotherapy and/or radiotherapy efficacy.

Main Methods:

  • Genotyping of four SNPs (ATM A60G, ERCC1 Asn118Asn, APE1 Asn148Glu, iASPP A67T) in 230 advanced NSCLC patients.
  • Patients received platinum-based chemotherapy, chemotherapy plus radiation, or radiotherapy alone.
  • TaqMan methods were used for SNP genotyping.

Main Results:

  • ERCC1 (Asn118Asn) genotype was significantly associated with response to chemotherapy alone; T allele carriers had poorer response (OR=4.10).
  • iASPP (A67T) genotype showed a significant association with response to combined chemotherapy and radiotherapy; A allele carriers had better response (OR=0.25).
  • An association was suggested for APE1, but not for ATM polymorphisms.

Conclusions:

  • Single nucleotide polymorphisms (SNPs) in ERCC1 and iASPP are associated with treatment response in NSCLC patients.
  • These findings support the role of genetic variations in DNA repair and apoptosis in modulating chemotherapy and radiotherapy effects.
  • Genetic profiling may aid in personalizing NSCLC treatment strategies.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...